These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 15609792)

  • 21. Limitations of the faecal occult blood test in screening for colorectal cancer.
    Delcò F; Sonnenberg A
    Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):119-26. PubMed ID: 10363196
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness modeling of colorectal cancer: computed tomography colonography vs colonoscopy or fecal occult blood tests.
    Lucidarme O; Cadi M; Berger G; Taieb J; Poynard T; Grenier P; Beresniak A
    Eur J Radiol; 2012 Jul; 81(7):1413-9. PubMed ID: 21444171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The economic evaluation of screening for colorectal cancer: Case of Iran.
    Barouni M; Ghaderi H; Shahmoradi MK
    Clin Lab; 2013; 59(5-6):667-74. PubMed ID: 23865368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood.
    Mandel JS; Church TR; Ederer F; Bond JH
    J Natl Cancer Inst; 1999 Mar; 91(5):434-7. PubMed ID: 10070942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis.
    Song K; Fendrick AM; Ladabaum U
    Gastroenterology; 2004 May; 126(5):1270-9. PubMed ID: 15131787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Markov's modeling for screening strategies for colorectal cancer.
    Barouni M; Larizadeh MH; Sabermahani A; Ghaderi H
    Asian Pac J Cancer Prev; 2012; 13(10):5125-9. PubMed ID: 23244122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Colorectal cancer screening comparing no screening, immunochemical and guaiac fecal occult blood tests: a cost-effectiveness analysis.
    van Rossum LG; van Rijn AF; Verbeek AL; van Oijen MG; Laheij RJ; Fockens P; Jansen JB; Adang EM; Dekker E
    Int J Cancer; 2011 Apr; 128(8):1908-17. PubMed ID: 20589677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic evaluation of colorectal cancer screening programs: Affordability for the health service.
    Coretti S; Ruggeri M; Dibidino R; Gitto L; Marcellusi A; Mennini FS; Cicchetti A
    J Med Screen; 2020 Dec; 27(4):186-193. PubMed ID: 31948342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
    Murphy J; Halloran S; Gray A
    BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes and cost evaluation of the first two rounds of a colorectal cancer screening program based on immunochemical fecal occult blood test in northern Italy.
    Parente F; Boemo C; Ardizzoia A; Costa M; Carzaniga P; Ilardo A; Moretti R; Cremaschini M; Parente EM; Pirola ME
    Endoscopy; 2013; 45(1):27-34. PubMed ID: 23254404
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endoscopist-directed propofol administration versus anesthesiologist assistance for colorectal cancer screening: a cost-effectiveness analysis.
    Hassan C; Rex DK; Cooper GS; Benamouzig R
    Endoscopy; 2012 May; 44(5):456-64. PubMed ID: 22531982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia.
    Ladabaum U; Mannalithara A
    Gastroenterology; 2016 Sep; 151(3):427-439.e6. PubMed ID: 27311556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cost-effectiveness of screening for colorectal cancer.
    Telford JJ; Levy AR; Sambrook JC; Zou D; Enns RA
    CMAJ; 2010 Sep; 182(12):1307-13. PubMed ID: 20624866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A simulation model for evaluating the medical and economic outcomes of screening strategies for colorectal cancer.
    Lejeune C; Arveux P; Dancourt V; Fagnani F; Bonithon-Kopp C; Faivre J
    Eur J Cancer Prev; 2003 Feb; 12(1):77-84. PubMed ID: 12548114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness analysis of colorectal cancer screening strategies in Singapore: a dynamic decision analytic approach.
    Wong SS; Leong AP; Leong TY
    Stud Health Technol Inform; 2004; 107(Pt 1):104-10. PubMed ID: 15360784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cost-effectiveness analysis on colorectal cancer screening program].
    Huang QC; Ye D; Jiang XY; Li QL; Yao KY; Wang JB; Jin MJ; Chen K
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jan; 38(1):65-68. PubMed ID: 28100379
    [No Abstract]   [Full Text] [Related]  

  • 37. Cost effectiveness of CT colonography for UK NHS colorectal cancer screening of asymptomatic adults aged 60-69 years.
    Lee D; Muston D; Sweet A; Cunningham C; Slater A; Lock K
    Appl Health Econ Health Policy; 2010; 8(3):141-54. PubMed ID: 20369905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fecal occult blood screening for colorectal cancer.
    Van Dam J; Bond JH; Sivak MV
    Arch Intern Med; 1995 Dec 11-25; 155(22):2389-402. PubMed ID: 7503597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16).
    Chen LS; Liao CS; Chang SH; Lai HC; Chen TH
    J Med Screen; 2007; 14(4):191-9. PubMed ID: 18078564
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.